BT-001 ESMO 2024
Category: BT-001 (EN)
Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
Transgene and BioInvent – first patient treated in Part B of Phase I trial
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
Transgene and bioinvent announce clinical collaboration
Transgene and BioInvent announce positive progress for BT-001
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
JB Marchand et al.AACR 2022Read the abstract here – Download the poster herePoster Presentation
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Transgene and BioInvent Announce Poster Presentation on BT-001
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
Semmrich M, Marchand J, Fend L, et alJournal for ImmunoTherapy of Cancer Download the publication herePublication